<DOC>
	<DOCNO>NCT02824913</DOCNO>
	<brief_summary>The purpose Phase 2a study ass change tear volume non-invasive technique Ultra High Resolution Optical Coherence Tomography ( UHR-OCT ) follow administration P-321 Ophthalmic Solution Placebo subject tear deficient dry eye disease .</brief_summary>
	<brief_title>Study Pharmacodynamic Activity P-321 Ophthalmic Solution Compared Placebo Subjects With Dry Eye Disease</brief_title>
	<detailed_description>This single-center , randomize , cross-over placebo control study evaluate change tear volume P-321 Ophthalmic Solution Placebo . The study enroll subject tear deficient dry eye disease receive sequentially one two treatment sequence : P-321 Ophthalmic Solution Placebo Placebo P-321 . The study consist two Phases : In Phase , subject treat different strength P-321 Ophthalmic Solution study design . Approximately twenty-four eligible subject complete study approximately 8 subject participate Phase 1 remainder 24 subject participate phase 2 . Decisions dose use Phase 2 make base Phase 1 data . The study consist three study visit : Screening Visit ( Visit 1 ) , two treatment visit ( Visit 2 Visit 3 ) . The primary secondary outcome measure assess treatment visit . Safety assessment include adverse event ( AEs ) .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Provide write informed consent 2 . Male female subject age 18 80 year 3 . Have history predominantly teardeficient dry eye mild moderate severity , support previous clinical diagnosis 4 . Have Schirmer 's test &gt; 1mm &lt; 10 mm 5 . Have normal lid anatomy 6 . Subjects must : 1 . Remain current medication duration study current medication regimen least past 28 day 1 . Have undergone refractive eye surgery either eye past 12 month 2 . Have undergone uncomplicated cataract surgery either eye past 3 month 3 . Have undergone previous eyelid surgery either eye 4 . Have undergone botulinum toxin ( BotoxTh1 equivalent ) injection periocular area within 3 month prior Visit 1 5 . Subjects systemic , multiorgan disease require active medical surgical treatment exclude exception subject SS GVHD 6 . Have punctal plug , punctal occlusion , history nasolacrimal duct obstruction 7 . Past present exposure keratopathy , neurotrophic keratopathy , lagophthalmos , trichiasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>